{
  "id": "5c83f858617e120c34000003",
  "type": "yesno",
  "question": "Is treatment with Bacillus Calmette Guerin used for bladder cancer?",
  "ideal_answer": "Intravesical Bacillus Calmette-Guerin (BCG) is the best treatment modality for progression of non-muscle invasive bladder cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29673806",
    "http://www.ncbi.nlm.nih.gov/pubmed/11989131",
    "http://www.ncbi.nlm.nih.gov/pubmed/17945285",
    "http://www.ncbi.nlm.nih.gov/pubmed/28916862",
    "http://www.ncbi.nlm.nih.gov/pubmed/19918272",
    "http://www.ncbi.nlm.nih.gov/pubmed/1732628",
    "http://www.ncbi.nlm.nih.gov/pubmed/3892051",
    "http://www.ncbi.nlm.nih.gov/pubmed/3892050",
    "http://www.ncbi.nlm.nih.gov/pubmed/29362915",
    "http://www.ncbi.nlm.nih.gov/pubmed/17997439",
    "http://www.ncbi.nlm.nih.gov/pubmed/21541499",
    "http://www.ncbi.nlm.nih.gov/pubmed/12031870",
    "http://www.ncbi.nlm.nih.gov/pubmed/16813873",
    "http://www.ncbi.nlm.nih.gov/pubmed/2231917",
    "http://www.ncbi.nlm.nih.gov/pubmed/2359181",
    "http://www.ncbi.nlm.nih.gov/pubmed/6757467",
    "http://www.ncbi.nlm.nih.gov/pubmed/19758621",
    "http://www.ncbi.nlm.nih.gov/pubmed/6381762"
  ],
  "snippets": [
    {
      "text": "Intravesical Bacillus Calmette-Guerin (BCG) is the best treatment modality for progression of non-muscle invasive bladder cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916862",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "this result indicates that they may be used as putative biomarkers for monitoring changes in bladder carcinogenesis in response to BCG immunotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916862",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "response of urothelial precancerous lesions to intravesical BCG treatment",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916862",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "bladder cancer (BC) is a major clinical issue.METHODS: We performed immunohistochemistry to assess the role of human epidermal growth factor receptor-2 (HER-2) and microsatellite instability (MSI) factors MutL homologue 1 (MLH1) and MutS homologue 2 (MSH2) in predicting recurrence and progression of T1 high-grade BCs having undergone transurethral resection of bladder tumor (TURBT) alone or TURBT\u2009+\u2009intravesical instillations of bacillus Calmette-Guerin (BCG).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29362915",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To evaluate the efficacy and safety of a tailored endovesical immunotherapy protocol with biweekly BCG for elderly Patients with high risk non muscle invasive bladder cancer ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29673806",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bacillus of Calmette-Guerin (BCG) therapy for high risk non muscle invasive bladder cancer treatment in older patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29673806",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BCG (Bacillus of Calmette Guerin) has been used for more than 20 years and is currently the most active agent for superficial bladder cancer therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12031870",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12031870",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Production of IL-5, a classical T(H)2 cytokine, following bacillus Calmette guerin immunotherapy of bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21541499",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Intravesical Bacillus Calmette-Guerin is used to treat patients with superficial bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1732628",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There is some evidence that BCG therapy improves survival and progression rates of patients with high-risk superficial bladder cancer decreasing the proportion who require radical cystectomy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12031870",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Local immunotherapy with bacillus Calmette-Guerin (BCG) is an effective and frequently used treatment for superficial bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11989131",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nIntravesical bacillus Calmette-Guerin is a viable therapeutic option in patients with high risk superficial bladder cancer and concomitant lymphoma or chronic lymphocytic leukemia, treatment with low dose oral steroids or treatment with inhaled steroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16813873",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE\nBacillus Calmette-Guerin is the most effective therapy for nonmuscle invasive bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19758621",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION\nBacillus Calmette-Guerin (BCG) is a live attenuated strain of Mycobacterium bovis that has been used to treat urothelial carcinoma since 1976, and has been reported to eradicate disease in more than 70% of patients with in situ and stage I disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19918272",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Intravesical administration of bacillus Calmette-Guerin has been shown to be highly effective treatment of superficial bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2231917",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/3892051",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We describe a 53 year- old man with a disseminated bacillus Calmette-Guerin (BCG) infection after intravescical instillation for bladder carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11989131",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We tested the hypothesis that tumor expression of natural cytotoxicity receptor ligands can serve as a predictive factor for the response to intravesical bacillus Calmette-Guerin in patients with nonmuscle invasive, high grade bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17945285",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bacillus Calmette-Guerin immunotherapy has been found by a number of investigators to be effective in the treatment and prevention of superficial bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/3892050",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pancreatic and psoas abscesses as a late complication of intravesical administration of bacillus Calmette-Guerin for bladder cancer: a case report and review of the literature.This case illustrates the fact that although intravesical administration of bacillus Calmette-Guerin is generally considered to be safe, it is not exempt from complications and these could appear immediately after treatment or as a delayed complication many years later.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19918272",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.The antitumoral effects of intravesical bacillus Calmette-Guerin against recurrent superficial urothelial bladder cancer seem to be linked to immunological effector mechanisms. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2359181",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer.Intravesical administration of bacillus Calmette-Guerin has been shown to be highly effective treatment of superficial bladder cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2231917",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.We treated 40 patients with superficial bladder cancer via intravesical bacillus Calmette-Guerin for 1) prophylaxis against tumor recurrence, 2) residual carcinoma or 3) flat carcinoma in situ. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/3892051",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Bacillus Calmette-Guerin immunotherapy for bladder cancer.Bacillus Calmette-Guerin immunotherapy has been found by a number of investigators to be effective in the treatment and prevention of superficial bladder cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/3892050",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.Intravesical bacillus Calmette-Guerin is a viable therapeutic option in patients with high risk superficial bladder cancer and concomitant lymphoma or chronic lymphocytic leukemia, treatment with low dose oral steroids or treatment with inhaled steroids. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16813873",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Our results suggest that intralesional bacillus Calmette-Guerin immunotherapy can afford long term protection from transplanted bladder cancer, and that live bacillus Calmette-Guerin is superior to levamisole and P3 + Re-glycolipid + bacillus Calmette-Guerin cell walls in the treatment of bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6381762",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A randomized controlled prospective evaluation of intravesical and percutaneous bacillus Calmette-Guerin immunotherapy was done in 57 patients with transitional cell carcinoma of the bladder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6757467",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Up to 90% of patients with high grade superficial bladder tumors experience tumor recurrence and up to 50% have progression despite bacillus Calmette-Guerin treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17945285",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We review how the bacillus Calmette-Guerin vaccine evolved to become standard therapy for superficial bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17997439",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We reviewed the historical literature describing the origin of the bacillus Calmette-Guerin vaccine as an anticancer agent and its singular success as the most effective immunotherapy used against a human neoplasm.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17997439",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}